CPDA-1- anticoagulant citrate phosphate dextrose adenine solution

CPDA-1 by

Drug Labeling and Warnings

CPDA-1 by is a Prescription medication manufactured, distributed, or labeled by Fenwal, Inc., Fenwal International, Inc.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • For component preparation using manual plasma extractors, use standard component processing and storage techniques.
  • If a platelet concentrate is to be prepared, it should be separated from the red blood cells within 8 hours after blood collection.
  • 17. When processing a multiple BLOOD-PACK unit, centrifuge primary and secondary containers to prepare CPD red blood cells, or CPDA-1 red blood cells as applicable.
  • 18. Place primary container in plasma extractor and express plasma into empty transfer pack container by releasing pressure plate and opening closure in tubing of primary container. (Break the cannula on top of the primary pack by holding the rigid part and bending 3 times laterally 90°. Make sure the plasma flows to the transfer pack).
  • 19. When desired amount of plasma has been removed, clamp tubing between Y and plasma container.
  • 20. If applicable, suspend ADSOL red cell preservation solution container, open closure in tubing (Break the stem of the cannula using the other hand by bending back and forth at 90° at least 3 times. Ensure the cannula is well broken by locating the broken part in the upper part of the housing) and drain contents into primary container of CPD red blood cells. Clamp tubing.
  • 21. Seal transfer tubing in three places after second segment number near primary container (leaving two segment numbers connected to the primary container) and cut middle seal being careful to avoid fluid splatter. For Double BLOOD-PACK unit codes, discard ADSOL solution container. For other ADSOL codes, the empty solution container may be used as a transfer pack container for further component preparation.
  • 22. If applicable, mix ADSOL red cell preservation solution and red cells thoroughly.
  • 23. Component Preparation (OPTIPAC™/OPTIPRESS™):
  • Refer to OPTIPRESS manual for detailed instructions.
  • For component preparation using an OPTIPAC, use standard component processing and storage techniques.
  • 24. Centrifuge the pack to separate blood component.
  • 25. Position the OPTIPAC primary pack in the OPTIPRESS.
  • 26. Put the additive solution container on the bench and the tubing through the lower clamp.
  • 27. Put the empty transfer packs on top of the OPTIPRESS and tubing through the upper clamp.
  • 28. Start the OPTIPRESS by pushing the “Press” button.
  • 29. Break the cannula on top of the primary pack by holding the rigid part and bending 3 times laterally 90°. Make sure the plasma flows to the transfer pack.
  • 30. As soon as the top clamp is closed, hold the base of the cannula on the additive solution container between the thumb and first finger. Break the stem of the cannula using the other hand by bending back and forth at 90° at least 3 times. Ensure the cannula is well broken by locating the broken part in the upper part of the housing.
  • 31. When the procedure is completed, both the upper and lower clamps occlude the tubing so as to prevent red cell contamination. At this point place a clip on the line at the top of the OPTIPAC to prevent any red cells travelling up the plasma line when the OPTIPAC has been removed from the OPTIPRESS.
  • 32. Seal the transfer pack containing plasma and the unit of red cells, leaving behind the OPTIPAC and the platelet pack.
  • 33. Push the “PRESS” button on the OPTIPRESS to release the pressure plate and remove the packs.
  • 34. After storage of the OPTIPAC, the primary pack, and the empty platelet container may be used to prepare other components according to blood center procedures.
  • 35. Storage:
  • Store suspended AS-1 red blood cells or suspended CPDA-1 whole blood/red blood cells (as applicable) between 1 and 6°C.
  • Infuse AS-1 red blood cells within 42 days of collection, and CPDA-1 whole blood/red blood cells within 35 days of collection.
  • NOTES:

  • - Protect container and tubing from sharp objects.
  • - When frozen, plastic is more fragile.
  • CAUTIONS TO BE TAKEN

  • - Do not use if there is visible sign of deterioration.
  • - Do not use if fluid path closures are loose or not intact.
  • - Do not use unless solution is clear and no leaks are detected.
  • Sterile, non-pyrogenic fluid path. Steam sterilized.

    Single use only. Do not vent.

    Dispose of container appropriately.

    Store at Controlled Room Temperature. USP Definition of “Controlled Room Temperature” United States Pharmacopeia, General Notices.
    United States Pharmacopeial Convention, Inc.
    12601 Twinbrook Parkway, Rockville, MD

    logo– Fabricante/Manufacturer

    logoFabricado por/Manufactured by:
    Fenwal International, Inc.
    Road 357, Km. 0.8
    Maricao, PR 00606

    Hecho en EE. UU. / Made in USA

    Importado y distribuido en India por:/
    Imported and distributed in India by:
    Fenwal India Pvt LtdUpper Ground Floor, Tower B
    DLF Building No. 10, DLF Cyber City
    DLF Phase II, Gurgaon 122 002,
    Haryana, India
    Import License No.: FF-504-14890

    Importado y distribuido en Indonesia por:/
    Imported and distributed in Indonesia by:
    PT. Medquest Jaya Global
    Menara Salemba 6th Floor
    Jl.Salemba Raya Kav 5-5A
    Jakarta-Indonesia 10440

    Importado y distribuido en Thailand por:/
    Imported and distributed in Thailand by:
    Fenwal (Thailand) Ltd.
    17th Fl. Thanapoom Tower
    1550 New Petchburi Rd., Makasan
    Rajthevi, Bangkok 10400
    Thailand
    Reg. No.:

    Importado y distribuido en Perú por:/
    Imported and distributed in Perú by:
    HERSIL S.A. LABORATORIOS INDUSTRIALES FARMACÉUTICOS
    Av. Los Frutales No. 220
    Ate, Lima 3 –Perú
    RUC: 20100060150
    Q.F. Responsable: Antonio Benitez Z.
    Reg. No.:

    Importado y distribuido en Venezuela por:/
    Imported and distributed in Venezuela by:
    SOLUCARE GT, C.A. RIF J-30512494-9
    en La Urbina, Caracas,
    Republica Bolivariana de Venezuela
    TELF (0212) 2436663
    Representante legal: Ynecel C. Obando M.MSAS 5635

    Importado y distribuido en Colombia por:/
    Imported and distributed in Colombia by:
    Fenwal Colombia Ltda.
    Centroempresa, Cali, Colombia
    Reg. No.: INVIMA-2006M-0000140-R1

    07-19-04-282 REV: A 01/2010

    FENWAL, BOLSANG, ADSOL, OPTIPRESS y OPTIPAC son Marcas Registradas de Fenwal, Inc.

    FENWAL, BLOOD-PACK, ADSOL, OPTIPRESS and OPTIPAC are trademarks of Fenwal, Inc.

    DONORCARE is a trademark of ITL Corporation.

    DONORCARE es una marca comercial de ITL Corporación.

    © 2010 Fenwal, Inc. Todos los derechos reservados. All rights reserved.

  • PACKAGE/LABEL DISPLAY PANEL

    REF R4R7295

    8 Units

    Fenwal™

    Double Blood-PackUnit Anticoagulant Citrate Phosphate Dextrose Adenine Solution (CPDA-1)

    PL 146 Plastic

    Rx Only

    Double Blood-Pack unit consisting of a primary pack containing 63 mL of CPDA-1 anticoagulant solution and one transfer pack without solution for collection of 450 mL of blood, 16 gauge needle.

    See instructions for use. Sterile, non-pyrogenic fluid path. Steam sterilized. Single use only. Do not vent. Do not use if there is any visible sign of deterioration. Dispose of container appropriately. Store at Controlled Room Temperature (refer to direction insert).

    Unused packs in open foil pouch may be kept 60 days by folding and securing open end of foil pouch, to prevent possible loss of moisture.

    Direct handling of product surfaces prior to extended storage in the foil pack may result in mold growth.

    Units removed from the foil pouch must be used within 4 days (96 hours). Units out of the foil pouch for longer than 4 days must be discarded.

    CPDA-1 formula: Each unit consists of a primary container with 63 mL of CPDA-1 USP Solution. Each 63 mL CPDA-1 solution contains 2.01 g Dextrose (monohydrate), USP, 1.66 g Sodium Citrate (dihydrate), USP, 206 mg Citric Acid (monohydrate), USP, 140 mg Monobasic Sodium Phosphate (monohydrate), USP, 17.3 mg Adenine, USP. Water for Injection USP to 63 mL.

    Manufactured by:

    Fenwal International, Inc.
    Road 357, Km. 0.8
    Maricao, PR 00606

    Made in USA

    Imported and distributed in India by:
    Fenwal India Pvt Ltd
    Upper Ground Floor, Tower B
    DLF Building No. 10
    DLF Cyber City, DLF Phase II
    Gurgaon 122 002,
    Haryana, India
    Import License No.: FF-504-14890
    MRP Rs: 169 (Inclusive of all taxes)

    Imported and distributed in Indonesia by:
    PT. Medquest Jaya Global
    Menara Salemba 6th Floor
    Jl.Salemba Raya Kav 5-5A
    Jakarta-Indonesia 10440
    Reg. No.: See instructions for use.

    FENWAL and BLOOD-PACK are trademarks of Fenwal, Inc.

    07-28-03-910 REV: A

    Double Blood-Pack™ Unit Anticoagulant Citrate Phosphate Dextrose Adenine Solution (CPDA-1) label
  • INGREDIENTS AND APPEARANCE
    CPDA-1 
    anticoagulant citrate phosphate dextrose adenine solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0942-6330
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Dextrose Monohydrate (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK) Dextrose Monohydrate2 g  in 63 mL
    Trisodium Citrate Dihydrate (UNII: B22547B95K) (Anhydrous Citric Acid - UNII:XF417D3PSL) Anhydrous Citric Acid1.66 g  in 63 mL
    Anhydrous Citric Acid (UNII: XF417D3PSL) (Anhydrous Citric Acid - UNII:XF417D3PSL) Anhydrous Citric Acid188 mg  in 63 mL
    Sodium Phosphate, Monobasic, Monohydrate (UNII: 593YOG76RN) (PHOSPHATE ION - UNII:NK08V8K8HR) Sodium Phosphate, Monobasic, Monohydrate140 mg  in 63 mL
    Adenine (UNII: JAC85A2161) (Adenine - UNII:JAC85A2161) Adenine17.3 mg  in 63 mL
    Inactive Ingredients
    Ingredient NameStrength
    Sodium Hydroxide (UNII: 55X04QC32I)  
    Water (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0942-6330-0263 mL in 1 BAG; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDABN77042005/25/2010
    Labeler - Fenwal, Inc. (794519020)
    Establishment
    NameAddressID/FEIBusiness Operations
    Fenwal International, Inc.091164590MANUFACTURE(0942-6330)

  • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.